Ceterix Announces Issuance of Key New Patent for Minimally Invasive Orthopaedic Procedures

Adds to Robust Intellectual Property Portfolio Totaling Over 160 Issued Claims

MENLO PARK, Calif. – September 8, 2014 – Ceterix® Orthopaedics, Inc., a developer of novel surgical tools that improve the ability to perform minimally invasive orthopaedic procedures, today announced the issuance of a new patent adding to the company’s existing patent portfolio. The company’s innovative NovoStitch® suture passer is used in the repair of meniscal tears and other soft-tissue joint injuries.

Ceterix’s new patent further protects the company’s unique products and methods that allow surgeons to arthroscopically pass suture through soft tissue in very tight joint compartments. The NovoStitch suture passer allows the placement of a circumferential compression stitch in the knee meniscus, which is tightly surrounded by critical structures such as nerves, arteries and cartilage. This enables orthopaedic surgeons to treat complex injuries that have not been amenable to repair in the past. The NovoStitch technology can also be utilized in minimally invasive hip and shoulder procedures. “This patent adds to our robust intellectual proper ty portfolio with more than 160 issued claims now protecting our approach,” said John McCu tcheon, president and CEO of Ceterix. “These patents are a testament to the inno vative nature of our NovoStitch technology now in use at more than 200 centers in the US.”

Arthroscopic surgery is a minimally invasive procedure in which an orthopaedic surgeon treats the damaged joint through small incisions using specialized tools and guided by a tiny camera called an arthroscope. Meniscus surgery is the most common arthroscopic procedure in the United States, with roughly one million performed annually.

About Ceterix Orthopaedics

Ceterix® Orthopaedics develops surgical tools that expand and improve what is possible for physicians who treat soft tissue injuries such as meniscus tears, hip and shoulder labrum tears, and rotator cuff tears. Founded in 2010 with the vision of improving outcomes of arthroscopic procedures, Ceterix’s novel suture passing device enables surgeons to place suture patterns that were previously only possible in open procedures, or not at all. The company is based in Menlo Park, Calif. and is backed by investors Novo Ventures, Versant Ventures and 5AM Ventures. For more information, please visit http://www.ceterix.com/cet/

US 8,821,518 B2- Suture Passing Instrument and Method

Media Contact:

Nicole Osmer

« Go Back